The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology: Results from the ATHENA HPV study

American Journal of Clinical Pathology

Volumn 137, Issue 2, 2012, Pages 295-303

  Stoler, Mark H ^a   Wright, Thomas C ^b,d   Sharma, Abha ^c   Zhang, Guili ^c   Apple, Raymond ^c   Wright, Teresa L ^c   Behrens, Catherine M ^c   Ferenczy, Alexander ^e  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Age stratification; ASC US; Cervical cancer screening; Cytology; Genotype; HPV DNA testing; Human papillomavirus; Triage

Indexed keywords

ADULT; AGE; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER CLASSIFICATION; CANCER GRADING; CANCER RISK; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84863038382     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPGW1V2BBWMOCX     Document Type: Article

References (31)

1. Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006. Arch Pathol Lab Med. 2010;134:331-335.
2. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119. (Pubitemid 34437346)
3. ALTS Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
4. Cox JT, Lorincz AT, Schiffman MH, et al. Human papillomavirus testing by Hybrid Capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995;172:946-954.
5. Wright TC Jr, Lorincz A, Ferris DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol. 1998;178:962-966. (Pubitemid 28247170)
6. Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335-337. (Pubitemid 46806325)
7. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002;94:102-107. (Pubitemid 34121289)
8. Stoler MH, Wright TC Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135:468-475.
9. Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648-659.
10. Bergeron C, Cas F, Fagnani F, et al. Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance: effect of age [in French]. Gynecol Obstet Fertil. 2006;34:312-316.
11. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
12. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500. (Pubitemid 351665417)
13. Einstein MH, Martens MG, Garcia FA, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol. 2010;118:116-122.
14. Kendall BS, Bush AC, Olsen CH, et al. Reflex high-risk human papillomavirus testing for women with atypical squamous cells of undetermined significance in cytologic smears: effects since implementation in a large clinical practice. Am J Clin Pathol. 2005;123:524-528. (Pubitemid 40418547)
15. Moss S, Gray A, Legood R, et al. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ. 2006;332:83-85. (Pubitemid 43099248)
16. Selvaggi SM. ASC-US and high-risk HPV testing: performance in daily clinical practice. Diagn Cytopathol. 2006;34:731-733. (Pubitemid 44663247)
17. Wright JD, Rader JS, Davila R, et al. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol. 2006;107:822-829.
18. Wright TC Jr, Ronnett BM, Ferenczy AF, et al. Precancerous lesions of the cervix. In: Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York, NY: Springer-Verlag; 2011.
19. von Knebel DM. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002;38:2229-2242.
20. INK4aimmunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35:210-220.
21. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34:1077-1087.
22. World Health Organization International Agency for Research on Cancer. Human Papillomaviruses. Lyon, France: IARC Press; 2011:255-313. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; vol 100B.
23. Confortini M, Bondi A, Cariaggi MP, et al. Interlaboratory reproducibility of liquid-based equivocal cervical cytology within a randomized controlled trial framework. Diagn Cytopathol. 2007;35:541-544. (Pubitemid 47435615)
24. QIAGEN Gaithersburg hc2 High-Risk HPV DNA Test Instructions for use. Gaithersburg, MD: QIAGEN; 2008.
25. Castle PE, Cox JT, Jeronimo J, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol. 2008;111:847-856. (Pubitemid 351482616)
26. INK4atesting significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133:395-406.
27. Jeronimo J, Massad LS, Schiffman M, and the National Institutes of Health/American Society for Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007;197:47.e1.
28. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1808-1816. (Pubitemid 40705386)
29. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
30. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079. (Pubitemid 41417924)
31. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. (Pubitemid 47371147)